Key Technologies
Our innovative company strategy covers a wide spectrum of expertise, including complex small-molecule chemistries, medicinal chemistry, cell line development and cell culture, protein purification, and protein modification (including site-specific conjugation, analytics, and formulation). We also have GMP manufacturing capabilities.
Byondis has a suite of proprietary technologies available to generate promising clinical candidates. This includes next generation ADCs containing our proprietary duocarmazine linker-drug (LD) technology ByonZine®.
ByonZine®
Byondis’ Duocarmazine Linker-Drug Technology
Cleavable DNA-damaging linker-drug
ByonZine® ADCs can effectively eliminate heterogeneous tumors via the unique target-mediated and bystander mechanisms of action
Kills both dividing and non-dividing cancer cells
Extremely low levels of free drug in circulation
Pipeline
Our diverse pipeline of proprietary next-generation ADCs reflects our expertise in research, lead identification, preclinical/clinical development, process development and manufacturing.
Platforms
Our antibody drug conjugate (ADC) technology platforms are generating potential first and best in class assets, including novel proprietary payloads, linker and drug conjugation and improved targeting. This includes clinically validated MOAs, dual payloads, tumor and site-specific release, optimized antibody scaffolds and increased tumor selectivity. These platforms are enabling us to forge a new pathway in ADC development and oncology treatment.
